Company intelligence / Profile preview

Clairity

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Clairity Breast is the first FDA-authorized AI tool to predict a woman's five-year risk of developing breast cancer from a routine screening mammogram. It has undergone multi-site external validation and is launching commercially in late 2025, aiming for more precise and equitable risk-based screening.

Therapeutic areas: Oncology
Modalities: DeviceArtificial intelligence software
Industry: Medical Imaging

Beyond the preview

Go deeper on Clairity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clairity.

Explore the full profile